1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

28 May 2024
Admin
News Article

Immorta Bio Announces a Significant Breakthrough in Treatment of Liver Failure

Overview

Immorta Bio Inc, a biotechnology company developing efficient and practical personalized stem cell platforms aimed at treating diseases of aging, has announced patent filing on successful treatment of the carbon tetrachloride model of liver failure using its PMSC-11 stem cell therapy. Data disclosed in its filed patent demonstrates PMSC-11 potently suppresses liver damage as detected by preserving albumin production and blocking catastrophic rises in liver enzymes which are typical in liver failure. Importantly, the administration of the PMSC-11 stem cell product induced a potent increase in a totally unexpected cytokine whose expression in some publications has been correlated with accelerated recovery from hepatic failure.

Words from Immorta Bio

"age than the patient,"" said Dr. Thomas Ichim, president and chief scientific officer of Immorta Bio.
"The PMSC-11 cells, utilized in the experiments reported today, demonstrated safety as well as therapeutic efficacy, supporting continued development of this ""First in Class"" Stem Cell Therapy for liver failure."

Liver Failure

"Liver Failure is the fifth leading cause of death world-wide with no therapeutic options besides transplantation. We are conducting pre-clinical experiments in animals using human cells to demonstrate safety and efficacy of these cells before applying to the FDA to begin clinical trials,"" said Dr. Vlad Bykoriz, chief medical officer of Immorta Bio.

Stem Cells

Stem cells have previously been demonstrated to possess some therapeutic effects on liver failure, however allogeneic stem cells, that have been mostly used so far, are eventually rejected by the patient.
And autologous adult stem cells are limited in numbers, and often dysfunctional because of preexisting conditions.
The PMSC product overcomes some of the shortcomings of existing stem cell therapeutics.
These cells are patient specific, ""biologically younger"", and can be created in unlimited numbers because they are derived from the embryonic-like PRC.

Words from Chairman: Immorta Bio

"Our vision of significant life extension is based on revivifying aged or damaged organs," said Dr. Boris Reznik, CEO and chairman of the company.
"We generate "Amenable Stem Cells" (ASC) from a tablespoon of patient's blood and utilize our proprietary technology to transform these ASC into "Personalized Regenerative Cells" (PRC). The PRC are very similar to the immortal embryonic stem cells and are generated by "reverse differentiation" of the ASC from the patient's blood.
These PRC should allow for creation and introduction of cells for any tissue or organ whose regeneration is desired. Today's announcement provides a glimpse into the potential power of our Stem Cell Revivify path to organ and eventually whole-body rejuvenation."

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!